September 19, 2006

Interleukin-5 receptor (IL-5R) ligands comprising amino sequences of formula TGGGDGYVX.sub.3VE X.sub.4 ARCPTCK, EGYVX.sub.3VE X.sub.4 ARCPTCK, EGYVX.sub.3VE X.sub.4 ARCPTCR, GYVX.sub.3VE X.sub.4 ARCPTCG, EGYVX.sub.3VE X.sub.4 ARCPTCG, GYVX.sub.3VE X.sub.4 ARCPTCR, and EGYVX.sub.3VE X.sub.4 AACPTCR, and methods of using the same, are described and claimed.

24

September 19, 2006

10/168,372

December 16, 1999

530/351   424/85.2 530/324 530/326 530/327 530/388.2 530/402

A61K   38/00   (20060101)   A61K   45/00   (20060101)   C07K   17/00   (20060101)  

530/351   530/326   530/327   530/324   530/388.22   530/402   424/85.2   514/13   514/12   514/14  

7482433 - Peptides and compounds that bind to the IL-5 receptor - Owned by Affymax, Inc. (Palo Alto, CA) Interleukin-5 receptor (IL-5R) ligands comprising amino sequences of formula TGGGDGYVX.sub.3VEX.sub.4ARCPTCK, EGYVX.sub.3VEX.sub.4ARCPTCK, EGYVX.sub.3VEX.sub.4ARCPTCR, GYVX.sub.3VEX.sub.4ARCPTCG, EGYVX.sub.3VEX.sub.4ARCPTCG, GYVX.sub.3VEX.sub.4ARCPTCR, and EGYVX.sub.3VEX.sub.4AACPTCR, and methods of using the same, are described and claimed.

7528104 - Peptides that bind to the erythropoietin receptor - Owned by Affymax, Inc. (Palo Alto, CA) The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.